Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
56
APLS Quote, Financials, Valuation and Earnings
Last price:
$24.66
Seasonality move
:
7.92%
Day range:
$24.36 - $25.18
52-week range:
$16.10 - $35.57
Dividend yield:
0%
P/E ratio:
83.00x
P/S ratio:
3.07x
P/B ratio:
7.77x
Volume:
3.2M
Avg. volume:
2.5M
1-year change:
-25.62%
Market cap:
$3.1B
Revenue:
$781.4M
EPS (TTM):
$0.30
Analysts' Opinion
-
Consensus RatingApellis Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 7 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $35.00, Apellis Pharmaceuticals, Inc. has an estimated upside of 43.57% from its current price of $24.65.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $19.00 representing 22.92% downside risk from its current price of $24.65.
Fair Value
-
According to the consensus of 18 analysts, Apellis Pharmaceuticals, Inc. has 43.57% upside to fair value with a price target of $35.00 per share.
APLS vs. S&P 500
-
Over the past 5 trading days, Apellis Pharmaceuticals, Inc. has underperformed the S&P 500 by -2.4% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Apellis Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Apellis Pharmaceuticals, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Apellis Pharmaceuticals, Inc. reported revenues of $458.6M.
Earnings Growth
-
Apellis Pharmaceuticals, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Apellis Pharmaceuticals, Inc. reported earnings per share of $1.66.
Enterprise value:
3.1B
EV / Invested capital:
--
Price / LTM sales:
3.07x
EV / EBIT:
38.72x
EV / Revenue:
3.06x
PEG ratio (5yr expected):
--
EV / Free cash flow:
39.59x
Price / Operating cash flow:
39.66x
Enterprise value / EBITDA:
37.93x
Gross Profit (TTM):
$901.8M
Return On Assets:
5.03%
Net Income Margin (TTM):
4.43%
Return On Equity:
18.94%
Return On Invested Capital:
6.35%
Operating Margin:
48.67%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $272.9M | $715.2M | $1B | $196.8M | $458.6M | |
| Gross Profit | $231.4M | $617.1M | $901.8M | $162.8M | $433.7M | |
| Operating Income | -$596.7M | -$223.3M | $80.4M | -$47.3M | $223.2M | |
| EBITDA | -$595M | -$221.5M | $82.1M | -$46.8M | $223.5M | |
| Diluted EPS | -$5.25 | -$2.04 | $0.30 | -$0.46 | $1.66 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $475.4M | $831.9M | $796.8M | $833.9M | $990.7M | |
| Total Assets | $525.7M | $872.9M | $818.2M | $901.9M | $1.1B | |
| Current Liabilities | $94.2M | $115.4M | $185.6M | $191.3M | $279.5M | |
| Total Liabilities | $583M | $565.5M | $585.9M | $664.7M | $657.6M | |
| Total Equity | -$57.3M | $307.4M | $232.3M | $237.1M | $401.2M | |
| Total Debt | $211.8M | $464.2M | $444M | $463.7M | $468.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$637.6M | -$205.1M | $78.9M | $34.1M | $108.5M | |
| Cash From Investing | $123.5M | -$379K | -$225K | -- | -$148K | |
| Cash From Financing | $382.5M | $149.3M | $3.6M | $2.5M | $793K | |
| Free Cash Flow | -$639.1M | -$205.6M | $78.6M | $34.1M | $108.3M | |
APLS
Sector
Market Cap
$3.1B
$27.9M
Price % of 52-Week High
69.3%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-0.33%
-1.49%
1-Year Price Total Return
-25.62%
-16.66%
Beta (5-Year)
0.368
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$24.88
200-day SMA
Buy
Level
$21.90
Bollinger Bands (100)
Buy
Level
21.29 - 27.05
Chaikin Money Flow
Sell
Level
-42M
20-day SMA
Buy
Level
$22.96
Relative Strength Index (RSI14)
Buy
Level
60.12
ADX Line
Buy
Level
27.31
Williams %R
Neutral
Level
-23.8971
50-day SMA
Buy
Level
$23.11
MACD (12, 26)
Buy
Level
0.85
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Sell
Level
-52.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.0849)
Sell
CA Score
(Annual)
Level (-2.1223)
Sell
Beneish M-Score
(Annual)
Level (18.1333)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (3.1876)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
Stock Forecast FAQ
In the current month, APLS has received 10 Buy ratings 7 Hold ratings, and 1 Sell ratings. The APLS average analyst price target in the past 3 months is $35.00.
-
Where Will Apellis Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Apellis Pharmaceuticals, Inc. share price will rise to $35.00 per share over the next 12 months.
-
What Do Analysts Say About Apellis Pharmaceuticals, Inc.?
Analysts are divided on their view about Apellis Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Apellis Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $19.00.
-
What Is Apellis Pharmaceuticals, Inc.'s Price Target?
The price target for Apellis Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $35.00 according to 18 Wall Street analysts, 10 of them rate the stock a Buy, 1 rates the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is APLS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Apellis Pharmaceuticals, Inc. is a Buy. 10 of 18 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of APLS?
You can purchase shares of Apellis Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Apellis Pharmaceuticals, Inc. shares.
-
What Is The Apellis Pharmaceuticals, Inc. Share Price Today?
Apellis Pharmaceuticals, Inc. was last trading at $24.66 per share. This represents the most recent stock quote for Apellis Pharmaceuticals, Inc.. Yesterday, Apellis Pharmaceuticals, Inc. closed at $24.65 per share.
-
How To Buy Apellis Pharmaceuticals, Inc. Stock Online?
In order to purchase Apellis Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get APLS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
APLS
Sector
P/E ratio
83.00x
23.85x
PEG ratio
--
-0.01x
P/B ratio
7.77x
1.81x
Price / LTM sales
3.07x
1.58x
Growth Metrics
APLS
Sector
Revenue growth
132.98%
4.62%
Earnings growth
458.67%
10.5%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.51
-$0.21
Profitability
APLS
Sector
Profitability FY 2024
$663.6M
$3.6M
Return on invested capital
6.35%
-31.87%
Return on assets
5.03%
-28.18%
Return on equity
18.94%
-37.63%
Earnings Date
Last Earnings Date
Oct
30
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Jan
29
Balance Sheet
APLS
Sector
Total cash
$480.6M
$26.4M
Short term investments
--
$25.7M
Total assets
$885.1M
$76.9M
Long term debt
$468.4M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
